About Indo Us Bio-Tech Limited
Data last updated:
Indo Us Bio-Tech Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the seed production and distribution segment of the agriculture sector. It was incorporated on 04 February 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L01122GJ2004PLC043550. Its GSTIN is 24AADCP5613Q1Z4 (Gujarat). The company holds 2 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 541304 and NSE: INDOUS.
The company has an authorised share capital of ₹32 Cr and a paid-up capital of ₹20.05 Cr. It was formerly known as Pellucid Bio-Tech Private Limited and Indo Us Bio-Tech Private Limited. It is led by directors including Jagdishkumar Devjibhai Ajudiya (Managing Director) and Malti Jagdishbhai Ajudia (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 309 Shanti Mall Satadhar Char Rasta Opp. Navrang Tower Sola Road, Ahmedabad, Gujarat, India – 380061.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹110.44 Cr, a growth of 6.4% compared to the previous year. For the same year it recorded a net profit of ₹13.12 Cr (net margin 11.9%) and EBITDA of ₹17.01 Cr (EBITDA margin 15.4%).
The company has about 29 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Indo Us Bio-Tech. As per MCA filings, the company has open charges of ₹47.86 Cr and satisfied charges of ₹17.46 Cr on record. Court records list 83 cases involving the company, including 71 filed by the company and 12 filed against it; 30 cases are pending. The company has 17 deals on record (16 market trades, 1 ipo); the latest was in March 2026. The company has 5 MSME Form 1 returns on record between 2019 and 2022, listing 44 overdue payments to 23 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website indousagriseeds.com.
Company details
Name history
Indo Us Bio-Tech has undergone 3 name changes throughout its history. The company was previously known as Pellucid Bio-Tech Private Limited, Indo Us Bio-Tech Private Limited, and Pollucid Bio-Tech Private Limited. The current legal name is Indo Us Bio-Tech Limited.
| Company Name | Status |
|---|---|
| Indo Us Bio-Tech Limited | Current |
| Pellucid Bio-Tech Private Limited | Previous |
| Indo Us Bio-Tech Private Limited | Previous |
| Pollucid Bio-Tech Private Limited | Previous |
CIN history
Indo Us Bio-Tech has one previous CIN (Corporate Identification Number): U01122GJ2004PTC043550. The current CIN is L01122GJ2004PLC043550, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L01122GJ2004PLC043550 | Current |
| U01122GJ2004PTC043550 | Previous |
Contact details
Indo Us Bio-Tech Limited's registered office is in Ahmedabad, Gujarat. Its website is indousagriseeds.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address309 Shanti Mall Satadhar Char Rasta Opp. Navrang Tower Sola Road, Ahmedabad, Gujarat, India – 380061
- IndustryAgriculture, Seed Production & Distribution
To see the full contact details of Indo Us Bio-Tech Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Indo Us Bio-Tech operates one associated brand: INDO US BIO-TECH. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Producer and supplier of seeds | indousagriseeds.com |
Business activity
The main business activity of Indo Us Bio-Tech is agriculture, forestry, fishing. In detail, this covers production of crops and animals.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| A | Agriculture, forestry, fishing | A1 | Production of crops and animals |
To see the full business activity and turnover split of Indo Us Bio-Tech Limited, buy the company report.
Financials of Indo Us Bio-Tech Limited
FY 2025-26 filings availableIndo Us Bio-Tech Limited reported revenue of ₹110.44 Cr (up 6.4% YoY) for FY 2025-26.
Financial Highlights
FY 2021-22 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|
| Income statement | |||
| Revenue | 50.06 | 40.11 | 39.76 |
| Revenue growth | +24.8% | +0.9% | - |
| EBITDA | 6.79 | 5.33 | 3.96 |
| EBITDA margin | +13.6% | +13.3% | +10.0% |
| Profit before tax | 5.31 | 3.92 | 2.86 |
| Net profit | 5.06 | 4.90 | 2.54 |
| Net profit margin | +10.1% | +12.2% | +6.4% |
| EPS (₹) | 5.52 | 8.07 | 4.18 |
| Balance sheet | |||
| Total assets | 52.44 | 33.73 | 25.68 |
| Net worth | 38.51 | 21.34 | 16.44 |
| Total debt | 12.84 | 11.57 | 8.58 |
| Cash & bank | 0.05 | 0.13 | 0.20 |
| Net working capital | 43.67 | 28.16 | 22.96 |
| Cash flow | |||
| Cash from operations | 2.70 | 0.16 | (0.84) |
| Cash from investing | (5.44) | (1.78) | (0.57) |
| Cash from financing | 2.65 | 1.55 | 1.53 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 110 | 104 | 72.84 | 61.74 | 50.05 | 40.09 | 39.76 |
| Revenue growth | +6.4% | +42.6% | +18.0% | +23.4% | +24.8% | +0.8% | - |
| EBITDA | 17.01 | 18.93 | 10.80 | 9.39 | 6.95 | 5.52 | 3.96 |
| EBITDA margin | +15.4% | +18.2% | +14.8% | +15.2% | +13.9% | +13.8% | +10.0% |
| Profit before tax | 13.92 | 16.52 | 8.80 | 7.38 | 5.49 | 4.12 | 2.86 |
| Net profit | 13.12 | 16.26 | 8.24 | 7.23 | 5.24 | 5.10 | 2.54 |
| Net profit margin | +11.9% | +15.7% | +11.3% | +11.7% | +10.5% | +12.7% | +6.4% |
| EPS (₹) | 6.54 | 8.11 | 4.11 | 7.22 | 5.71 | 8.40 | 4.18 |
| Balance sheet | |||||||
| Total assets | - | 93.41 | 77.12 | 67.07 | 52.47 | 33.83 | 25.68 |
| Net worth | - | 78.52 | 62.75 | 54.50 | 38.88 | 21.54 | 16.44 |
| Total debt | - | 14.84 | 14.33 | 11.60 | 12.50 | 11.48 | 8.58 |
| Cash & bank | - | 0.25 | 1.10 | 0.19 | 0.05 | 0.13 | 0.20 |
| Net working capital | - | 82.29 | 65.76 | 57.51 | 43.96 | 28.28 | 22.96 |
| Cash flow | |||||||
| Cash from operations | - | 1.42 | 2.22 | 0.53 | 2.91 | 0.22 | (0.84) |
| Cash from investing | - | (0.79) | (2.53) | (6.67) | (5.40) | (1.75) | (0.57) |
| Cash from financing | - | (1.48) | 1.22 | 6.29 | 2.41 | 1.46 | 1.53 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.99 | 26.02 | 22.80 | 30.85 | 30.77 | 33.38 | 23.56 | 22.17 |
| Revenue growth (YoY) | +7.2% | -22.1% | -3.2% | +39.2% | +24.5% | - | - | - |
| Other income | 0.12 | 0.02 | 0.01 | 0.03 | 0.00 | 0.12 | 0.02 | 0.02 |
| Total expenses | 29.03 | 22.80 | 18.65 | 26.68 | 25.30 | 28.80 | 18.02 | 17.05 |
| EBITDA | 3.96 | 3.22 | 4.15 | 4.17 | 5.47 | 4.58 | 5.54 | 5.12 |
| EBITDA margin | +12.0% | +12.4% | +18.2% | +13.5% | +17.8% | +13.7% | +23.5% | +23.1% |
| Depreciation | 0.27 | 0.27 | 0.22 | 0.21 | 0.20 | 0.56 | 0.16 | 0.18 |
| Interest | 0.74 | 0.60 | 0.77 | 0.42 | 0.45 | 0.26 | 0.38 | 0.52 |
| Profit before tax | 3.07 | 2.37 | 3.17 | 3.57 | 4.82 | 3.88 | 5.02 | 4.44 |
| Tax | 0.04 | 0.41 | 0.17 | 0.11 | 0.12 | 0.19 | (0.04) | 0.09 |
Financial Statements
| Particulars | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|
| Revenue | 50.06 | 40.11 | 39.76 |
| Revenue growth | +24.8% | +0.9% | - |
| Other income | 0.18 | 0.04 | 0.01 |
| Total expenses | 43.27 | 34.78 | 35.80 |
| Employee cost | 0.48 | 0.33 | 0.35 |
| EBITDA | 6.79 | 5.33 | 3.96 |
| EBITDA margin | +13.6% | +13.3% | +10.0% |
| Depreciation | 0.46 | 0.27 | 0.23 |
| Interest | 1.20 | 1.18 | 0.88 |
| Profit before tax | 5.31 | 3.92 | 2.86 |
| Tax | 0.25 | (0.97) | 0.33 |
| Net profit | 5.06 | 4.90 | 2.54 |
| Net profit margin | +10.1% | +12.2% | +6.4% |
| EPS (₹) | 5.52 | 8.07 | 4.18 |
| Particulars | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 9.17 | 6.07 | 6.07 |
| Reserves & surplus | 29.34 | 15.27 | 10.37 |
| Shareholders' funds (net worth) | 38.51 | 21.34 | 16.44 |
| Minority interest | 0.00 | 0.00 | 0.00 |
| Secured loans | 4.12 | 2.51 | 0.08 |
| Unsecured loans | 8.72 | 9.06 | 8.50 |
| Total debt | 12.84 | 11.57 | 8.58 |
| Total liabilities | 52.44 | 33.73 | 25.68 |
| Assets | |||
| Gross block | 5.55 | 2.37 | 1.41 |
| Net block | 5.55 | 2.37 | 1.41 |
| Capital work in progress | 2.32 | 1.99 | 1.28 |
| Investments | 0.00 | 0.00 | 0.00 |
| Inventories | 23.36 | 11.88 | 9.15 |
| Sundry debtors | 20.55 | 24.71 | 20.98 |
| Cash & bank balances | 0.05 | 0.13 | 0.20 |
| Loans & advances | 2.89 | 1.42 | 1.58 |
| Total current assets | 46.85 | 38.14 | 31.91 |
| Total current liabilities | 3.18 | 9.98 | 8.95 |
| Net working capital | 43.67 | 28.16 | 22.96 |
| Total assets | 52.44 | 33.73 | 25.68 |
| Particulars | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|
| Opening cash | 0.13 | 0.20 | 0.08 |
| Net cash from operating activities | 2.70 | 0.16 | (0.84) |
| Net cash from investing activities | (5.44) | (1.78) | (0.57) |
| Net cash from financing activities | 2.65 | 1.55 | 1.53 |
| Net change in cash | (0.09) | (0.07) | 0.12 |
| Closing cash | 0.05 | 0.13 | 0.20 |
| Particulars | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|
| Growth | |||
| Sales growth | +24.8% | +0.9% | - |
| EBITDA growth | +27.4% | +34.6% | - |
| PBT growth | +35.5% | +37.1% | +9997.0% |
| Net income growth | +3.3% | +92.9% | - |
| Profitability & leverage | |||
| Net income margin | +10.1% | +12.2% | +6.4% |
| Return on capital employed | +15.1% | +17.2% | +14.6% |
| Return on net worth | +16.9% | +25.9% | +15.4% |
| Debt / equity | 0.41 | 0.53 | 0.52 |
| Long-term debt / equity | 0.12 | 0.11 | 0.05 |
| Interest cover | 18.96 | 23.32 | 23.59 |
| Efficiency & per share | |||
| Fixed asset turnover | 12.64 | 21.22 | 28.20 |
| Inventory turnover | 2.84 | 3.81 | 4.35 |
| Debtors turnover | 2.21 | 1.76 | 1.90 |
| EPS (₹) | 5.52 | 8.07 | 4.18 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 42.01 | 35.17 | 27.10 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.99 | 26.02 | 22.80 | 30.85 | 30.77 | 33.38 | 23.56 | 22.17 |
| Revenue growth (YoY) | +7.2% | -22.1% | -3.2% | +39.2% | +24.5% | - | - | - |
| Other income | 0.12 | 0.02 | 0.01 | 0.03 | 0.00 | 0.12 | 0.02 | 0.02 |
| Total expenses | 29.03 | 22.80 | 18.65 | 26.68 | 25.30 | 28.80 | 18.02 | 17.05 |
| EBITDA | 3.96 | 3.22 | 4.15 | 4.17 | 5.47 | 4.58 | 5.54 | 5.12 |
| EBITDA margin | +12.0% | +12.4% | +18.2% | +13.5% | +17.8% | +13.7% | +23.5% | +23.1% |
| Depreciation | 0.27 | 0.27 | 0.22 | 0.21 | 0.20 | 0.56 | 0.16 | 0.18 |
| Interest | 0.74 | 0.60 | 0.77 | 0.42 | 0.45 | 0.26 | 0.38 | 0.52 |
| Profit before tax | 3.07 | 2.37 | 3.17 | 3.57 | 4.82 | 3.88 | 5.02 | 4.44 |
| Tax | 0.04 | 0.41 | 0.17 | 0.11 | 0.12 | 0.19 | (0.04) | 0.09 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 110 | 104 | 72.84 | 61.74 | 50.05 | 40.09 | 39.76 |
| Revenue growth | +6.4% | +42.6% | +18.0% | +23.4% | +24.8% | +0.8% | - |
| Other income | 0.05 | 0.18 | 0.32 | 0.02 | 0.18 | 0.04 | 0.01 |
| Total expenses | 93.43 | 84.91 | 62.04 | 52.35 | 43.10 | 34.57 | 35.80 |
| Employee cost | 0.00 | 0.89 | 0.93 | 1.30 | 0.48 | 0.34 | 0.35 |
| EBITDA | 17.01 | 18.93 | 10.80 | 9.39 | 6.95 | 5.52 | 3.96 |
| EBITDA margin | +15.4% | +18.2% | +14.8% | +15.2% | +13.9% | +13.8% | +10.0% |
| Depreciation | 0.90 | 1.10 | 0.80 | 0.83 | 0.44 | 0.26 | 0.23 |
| Interest | 2.24 | 1.49 | 1.52 | 1.20 | 1.20 | 1.18 | 0.88 |
| Profit before tax | 13.92 | 16.52 | 8.80 | 7.38 | 5.49 | 4.12 | 2.86 |
| Tax | 0.80 | 0.26 | 0.56 | 0.15 | 0.25 | (0.97) | 0.33 |
| Net profit | 13.12 | 16.26 | 8.24 | 7.23 | 5.24 | 5.10 | 2.54 |
| Net profit margin | +11.9% | +15.7% | +11.3% | +11.7% | +10.5% | +12.7% | +6.4% |
| EPS (₹) | 6.54 | 8.11 | 4.11 | 7.22 | 5.71 | 8.40 | 4.18 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 20.05 | 20.05 | 10.03 | 9.17 | 6.07 | 6.07 |
| Reserves & surplus | - | 58.47 | 42.70 | 44.47 | 29.71 | 15.47 | 10.37 |
| Shareholders' funds (net worth) | - | 78.52 | 62.75 | 54.50 | 38.88 | 21.54 | 16.44 |
| Secured loans | - | 2.21 | 2.82 | 2.46 | 4.12 | 2.51 | 0.08 |
| Unsecured loans | - | 12.63 | 11.51 | 9.14 | 8.38 | 8.97 | 8.50 |
| Total debt | - | 14.84 | 14.33 | 11.60 | 12.50 | 11.48 | 8.58 |
| Total liabilities | - | 93.41 | 77.12 | 67.07 | 52.47 | 33.83 | 25.68 |
| Assets | |||||||
| Gross block | - | 14.53 | 10.31 | 7.37 | 5.54 | 2.33 | 2.82 |
| Net block | - | 10.23 | 6.69 | 7.37 | 5.54 | 2.33 | 1.40 |
| Capital work in progress | - | 0.00 | 3.78 | 1.37 | 2.32 | 1.99 | 1.28 |
| Investments | - | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Inventories | - | 70.69 | 51.74 | 26.91 | 23.36 | 11.88 | 9.15 |
| Sundry debtors | - | 15.00 | 19.05 | 24.74 | 20.54 | 24.69 | 20.98 |
| Cash & bank balances | - | 0.25 | 1.10 | 0.19 | 0.05 | 0.13 | 0.20 |
| Loans & advances | - | 0.79 | 1.21 | 8.07 | 3.11 | 1.43 | 1.58 |
| Total current assets | - | 86.73 | 73.10 | 59.91 | 47.06 | 38.13 | 31.91 |
| Total current liabilities | - | 4.44 | 7.34 | 2.40 | 3.10 | 9.85 | 8.95 |
| Net working capital | - | 82.29 | 65.76 | 57.51 | 43.96 | 28.28 | 22.96 |
| Total assets | - | 93.41 | 77.12 | 67.07 | 52.47 | 33.83 | 25.68 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 1.10 | 0.19 | 0.05 | 0.13 | 0.20 | 0.08 |
| Net cash from operating activities | - | 1.42 | 2.22 | 0.53 | 2.91 | 0.22 | (0.84) |
| Net cash from investing activities | - | (0.79) | (2.53) | (6.67) | (5.40) | (1.75) | (0.57) |
| Net cash from financing activities | - | (1.48) | 1.22 | 6.29 | 2.41 | 1.46 | 1.53 |
| Net change in cash | - | (0.85) | 0.91 | 0.14 | (0.08) | (0.07) | 0.12 |
| Closing cash | - | 0.25 | 1.10 | 0.19 | 0.05 | 0.13 | 0.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +6.4% | +42.6% | +18.0% | +23.4% | +24.8% | +0.8% | - |
| EBITDA growth | -10.1% | +75.3% | +15.0% | +35.1% | +25.9% | +39.4% | - |
| PBT growth | -15.7% | +87.7% | +19.2% | +34.4% | +33.3% | +44.1% | +1.8% |
| Net income growth | -19.3% | +97.3% | +14.0% | +38.0% | +2.8% | +100.8% | - |
| Revenue CAGR (3Y) | +21.4% | +27.5% | +22.0% | +15.8% | +12.3% | +10.9% | +17.5% |
| EBITDA CAGR (3Y) | +21.9% | +39.7% | +25.1% | +33.4% | +26.5% | +26.6% | +46.9% |
| Profitability & leverage | |||||||
| Net income margin | +11.9% | +15.7% | +11.3% | +11.7% | +10.5% | +12.7% | +6.4% |
| Return on capital employed | - | +21.1% | +14.3% | +14.4% | +15.5% | +17.9% | +16.1% |
| Return on net worth | - | +23.0% | +14.1% | +15.5% | +17.4% | +26.9% | +16.7% |
| Debt / equity | - | 0.21 | 0.22 | 0.26 | 0.40 | 0.53 | 0.49 |
| Long-term debt / equity | - | 0.04 | 0.04 | 0.05 | 0.11 | 0.11 | 0.05 |
| Interest cover | 13.90 | 8.36 | 15.20 | 14.02 | 18.43 | 22.43 | 23.59 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 8.36 | 8.24 | 9.56 | 12.72 | 15.57 | 14.73 |
| Inventory turnover | - | 1.70 | 1.85 | 2.46 | 2.84 | 3.81 | 4.00 |
| Debtors turnover | - | 6.10 | 3.33 | 2.73 | 2.21 | 1.76 | 2.65 |
| EPS (₹) | 6.54 | 8.11 | 4.11 | 7.22 | 5.71 | 8.40 | 4.18 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 39.16 | 31.29 | 54.35 | 42.41 | 35.50 | 27.10 |
To see the full year-wise statements and ratios of Indo Us Bio-Tech Limited, buy the company report.
Board of directors of Indo Us Bio-Tech Limited
Indo Us Bio-Tech has 6 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Malti Jagdishbhai Ajudia Also directs: Indo Us Organic Agri Private Limited, Indo-Us Agriseeds Limited | Whole-Time Director | 01 Nov 2008 | 17 Years 11 Months | Current |
| Jagdishkumar Devjibhai Ajudiya | Managing Director | 04 Feb 2004 | 22 Years 8 Months | Current |
| Priyanka Samarth Patel | Director | 23 Nov 2017 | 8 Years 10 Months | Current |
| Ritaben Nileshbhai Kikani Also directs: Kavyansh Pack LLP | Director | 01 Mar 2019 | 7 Years 7 Months | Current |
| Shilpa Chetanbhai Thumar | Director | 05 Aug 2021 | 5 Years 2 Months | Current |
| Hemanshi Darsh Soni | Director | 21 Apr 2026 | 0 Years 6 Months | Current |
Auditor
Indo Us Bio-Tech Limited is audited by Gautam N Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Gautam N Associates | FY 2023 | 103117W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 68.30%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 31.70%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 68.30% | 68.30% | 70.20% | 70.20% |
| Public | 31.70% | 31.70% | 29.80% | 29.80% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 19 Jun 2026 | 101320806 | Axis Bank Limited | ₹25 Lakh | Open | |
| 24 Jun 2025 | 101127905 | Axis Bank Limited | ₹44.05 Cr | Open | |
| 18 Apr 2023 | 100716412 | Axis Bank Limited | ₹2 Cr | Open | |
| 20 Sep 2022 | 100658186 | Axis Bank Limited | ₹1.45 Cr | Open | |
| 16 Jun 2022 | 100588688 | Others | ₹10.5 Lakh | Open |
To see the full charge records of Indo Us Bio-Tech Limited, buy the company report.
Total charge records: 9 View all charges
Deals & funding
Indo Us Bio-Tech Limited has 17 deals on record (16 market trades, 1 ipo); the latest was in March 2026.
Deals on record (5 of 17)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2026 | Market trade | ₹1.58 Cr | Seller: an individual |
| Jul 2022 | Market trade | ₹58.3 Lakh | Buyer: an individual |
| Mar 2021 | Market trade | ₹30.4 Lakh | Buyer: an individual Seller: an individual |
| Aug 2018 | Market trade | ₹51.2 Lakh | Buyer: Pratik Rajendra Gandhi Huf Seller: Beeline Broking Limited |
| May 2018 | Market trade | ₹16.5 Lakh | Seller: Barbelo Estates LLP |
To see the full deal history of Indo Us Bio-Tech Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Indo Us Bio-Tech Limited has 83 court cases on record: 71 filed by Indo Us Bio-Tech, 12 filed against it. 30 cases are pending and 53 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 81 | 10 | 30 |
| High courts | 2 | 2 | 0 |
Cases on record (5 of 83)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Ahmedabad, Gujarat | Commercial matter | Filed by the company against Cybrid Crop Sciences Pvt. Ltd. and 2 others | Pending |
| District court, Indore, Madhya Pradesh | Court case (RCS B) | Filed against the company by Bhanpurawala Agencies Pvt.Ltd. Indore Through Sunil Gang | Pending |
| District court, Ahmedabad, Gujarat | Court case (SPCS) | Filed against the company by M/S Super Seeds Private Limited | Pending |
| High Court | Court case (REVP) | Filed against the company by Ecl Agrotech Limited Through Its Authorized Signatory Shri Ram Kesh Singh | Disposed |
| High Court, CHHATTISGARH | Writ petition | Filed against the company by Ecl Agrotech Limited | Disposed |
To see the full case history of Indo Us Bio-Tech Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Indo Us Bio-Tech Limited has 5 MSME Form 1 returns on record between 2019 and 2022, listing 44 overdue payments to 23 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 23)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Excel Pneumatics | |||
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Indo Us Bio-Tech Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Indo Us Bio-Tech Limited has a workforce of 29 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.
GST
Indo Us Bio-Tech has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AADCP5613Q1Z4 | Gujarat | Active | 01 Jul 2017 |
| 29AADCP5613Q1ZU | Karnataka | Active | 07 Aug 2021 |
To see the full GST registrations and return filing status of Indo Us Bio-Tech Limited, buy the company report.
Recent activity
Indo Us Bio-Tech Limited has 21 board changes on record since 2004: 14 appointments and 7 cessations. The latest: Hemanshi Darsh Soni was appointed as Director on 21 Apr 2026.
28 earlier events are in the company report.
News
Frequently asked questions
Indo Us Bio-Tech is an active public limited company based in Ahmedabad, Gujarat, India. The company works in seed production and distribution, within the agriculture industry. It was incorporated on 04 February 2004 (22+ years old) and is registered under CIN L01122GJ2004PLC043550. Listed on BSE: 541304 and NSE: INDOUS.
Indo Us Bio-Tech reported revenue of ₹110.44 Cr for FY 2025-26 (up 6.4% YoY) based on standalone financials.
Indo Us Bio-Tech has 6 current directors:
- Jagdishkumar Devjibhai Ajudiya - Managing Director
- Malti Jagdishbhai Ajudia - Whole-Time Director
- Priyanka Samarth Patel - Director
- Ritaben Nileshbhai Kikani - Director
- Shilpa Chetanbhai Thumar - Director
- Hemanshi Darsh Soni - Director
The latest financial statements of Indo Us Bio-Tech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Indo Us Bio-Tech is 24AADCP5613Q1Z4, registered in Gujarat. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 29AADCP5613Q1ZU (Karnataka).
The CIN (Corporate Identification Number) of Indo Us Bio-Tech is L01122GJ2004PLC043550. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Indo Us Bio-Tech is a listed company as per MCA records. Its shares are listed on both BSE (code: 541304) and NSE (symbol: INDOUS).
Indo Us Bio-Tech has 83 court cases on record: 71 filed by the company and 12 filed against it. 30 are pending. Most are in the district courts.
Indo Us Bio-Tech was incorporated on 04 February 2004, making it 22+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Indo Us Bio-Tech has 17 deals on record (16 market trades, 1 ipo); the latest was in March 2026.
Hemanshi Darsh Soni was appointed as Director on 21 Apr 2026. Nehaben Sachinbhai Patel was appointed as Director on 05 Aug 2021. Samarth Nileshbhai Patel ceased to be Director on 05 Aug 2021. Indo Us Bio-Tech has 21 board changes on record in total.